

## Special Issue

# 10th Anniversary of Biomedicines—Pathogenesis and Innovative Therapies in Ovarian Cancer

### Message from the Guest Editors

Ovarian Cancer is the most lethal gynecological disease and is characterized by heterogeneity, a high risk of relapse and the development of chemoresistance; Genetic and epigenetic factors and microenvironment characteristics influence the progression of the disease and its response to therapy. The cornerstone of treatment has been maximal-effort surgical cytoreduction combined with cytotoxic chemotherapy, mainly represented by combinations of carboplatin and paclitaxel, both in adjuvant and metastatic settings. An estimated 80–85% of patients with OC who achieve full remission following first-line platinum-based therapy will develop disease recurrence, and the median survival for these patients ranges from 12 months to 24 months. Except for bevacizumab and poly ADP-ribose polymerase inhibitors, there are few other options for women with platinum-resistant OC. It is, therefore, particularly important to deepen the pathobiology of the tumor itself, and further understand how it is influenced by the microenvironment and by the genetic heterogeneity present not only in cancer from different patients, but also within a single cancer.

---

### Guest Editors

Dr. Francesca Magherini

Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, Università degli Studi di Firenze, Florence, Italy

Dr. Tania Gamberi

Department of Clinical and Preclinical Biomedical Sciences, University of Florence, Florence, Italy

---

### Deadline for manuscript submissions

closed (30 April 2023)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/111042](https://mdpi.com/si/111042)

*Biomedicines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).